LGVN Stock Overview
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Longeveron Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.97 |
| 52 Week High | US$4.58 |
| 52 Week Low | US$1.50 |
| Beta | 0.82 |
| 1 Month Change | -4.37% |
| 3 Month Change | -25.38% |
| 1 Year Change | -47.61% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -73.41% |
Recent News & Updates
Recent updates
Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?
Nov 17
Longeveron Inc.: A New Approach To Treat Alzheimer's
Oct 09Longeveron spikes after FDA’s Fast Track Designation for lead candidate
Aug 31Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?
Jul 15Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference
Jul 07Longeveron: Small-Cap Biotech Targeting Large Alzheimer's Market
May 06Companies Like Longeveron (NASDAQ:LGVN) Are In A Position To Invest In Growth
Apr 03Longeveron: Speculative Biotech Worth A Look On Rare Disease, Aging, And Alzheimer's Focuses
Feb 15Longeveron: Spooky Social-Media Generated Spike Signifies Nothing
Nov 29Is Longeveron (NASDAQ:LGVN) In A Good Position To Deliver On Growth Plans?
Nov 20Shareholder Returns
| LGVN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.0% | 2.3% | 0.5% |
| 1Y | -47.6% | -7.9% | 11.0% |
Return vs Industry: LGVN underperformed the US Biotechs industry which returned -7.9% over the past year.
Return vs Market: LGVN underperformed the US Market which returned 11% over the past year.
Price Volatility
| LGVN volatility | |
|---|---|
| LGVN Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: LGVN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: LGVN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 20 | Mohamed Wa'el Hashad | https://longeveron.com |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer’s disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Longeveron Inc. Fundamentals Summary
| LGVN fundamental statistics | |
|---|---|
| Market Cap | US$46.55m |
| Earnings (TTM) | -US$20.64m |
| Revenue (TTM) | US$767.00k |
61.0x
P/S Ratio-2.3x
P/E RatioIs LGVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LGVN income statement (TTM) | |
|---|---|
| Revenue | US$767.00k |
| Cost of Revenue | US$599.00k |
| Gross Profit | US$168.00k |
| Other Expenses | US$20.81m |
| Earnings | -US$20.64m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 21.90% |
| Net Profit Margin | -2,691.00% |
| Debt/Equity Ratio | 0% |
How did LGVN perform over the long term?
See historical performance and comparison